Loading…
← CockpitCompetitor Analysis › EKTA-B.ST Elekta AB Class BOpen in the cockpit ↗

Elekta AB Class BEKTA-B.STCompetitor analysis, valuation and peers

Sweden · SEK·Health Care›Medical Specialties

Swedish maker of radiation-therapy and radiosurgery equipment (linear accelerators, Gamma Knife) used to treat cancer and brain conditions.

≈ A radiation-oncology equipment maker like a smaller Varian Medical SystemsMomentum strong 70
Mkt cap
$2.35B
US dollars, full cap
Free float
98%
of shares outstanding
$/day
$7.97M
20-day average traded
Fwd P/E
15.3×
forward earnings
ROIC−WACC
-0.6 pp
WACC 7.4%
Hurdle
+7 pp
Req g minus delivered
Next earnings
7 days
25 Nov 2026
Close · SEKSEK 62.50
1D-0.2%
1W+0.9%
1M+12.0%
3M+11.3%
6M-0.1%
YTD+10.1%
1Y+38.5%
ATR %2.4%
52w lowhigh6.3% off high

What Elekta does

Swedish maker of radiation-therapy and radiosurgery equipment (linear accelerators, Gamma Knife) used to treat cancer and brain conditions.

Sells systems to hospitals as large capital purchases, often through public tenders, which makes orders lumpy, then earns steadier service and upgrade income on the installed base for many years. Gamma Knife is the older line, built on radiosurgery pioneered by founder Lars Leksell; the Leksell family remains a major shareholder.

In one line: A radiation-oncology equipment maker like a smaller Varian Medical Systems.

Products and services

  • Linear accelerators (radiotherapy)
  • Gamma Knife radiosurgery systems
  • Treatment planning software

Customers

  • Hospitals
  • Cancer treatment centers

Where it sits in the supply chain

  • Health Care
  • Medical devices
  • Radiation therapy equipment…

What could go right

  • Global cancer-incidence growth driving equipment demand
  • Emerging-market hospital capex

What could go wrong

  • Long, lumpy capital-equipment sales cycles
  • Hospital capex budget constraints

Moat: narrow (IP / patents, installed base, regulatory licence). Regulatory-approved, capital-intensive equipment with a large installed base creates service/upgrade revenue stickiness.

Headquarters: Stockholm, Sweden · Founded: 1972 · Employees: 4,102

Named competitors

Elekta at a glance

Size Elekta (EKTA-B.ST) is a Sweden Health Care company (Medical Specialties) with a market value of $2.35B, the 69th largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 62.50 on 18 Nov 2026.

Performance Over six months the shares fell 0.1%, against +1.1% for the median peer and +2.8% for the Sweden market (cap-weighted) — 10th lowest of 20 in its peer set.

Growth Revenue fell 6.9% over the last twelve months (peer median +7.5%); the operating margin is 6.3% (peer median 11.8%).

Valuation It trades at 15.3× forward earnings against a peer median of 24.3× (3rd cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.6 points below its cost of capital (7.4% WACC).

Next results Next results expected around 25 Nov 2026 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 104EKTA-B.ST 101
Six months, rebased to 100: Elekta against the median of its 20 peers (local-currency closes).

Elekta financials

Reported figures in SEK; fiscal year ends 2026-04-30. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueSEK 16.6BSEK 16.7BSEK 18.0BSEK 18.1BSEK 16.9B
Revenue growth—-7%-1%+7%—
Gross profitSEK 6.41BSEK 5.14BSEK 5.62BSEK 5.75BSEK 5.39B
EBITDASEK 1.77BSEK 3.41BSEK 3.51BSEK 3.50BSEK 2.99B
Net income-SEK 362M-SEK 519MSEK 237MSEK 1.30BSEK 943M
Free cash flowSEK 2.44BSEK 2.34BSEK 2.43BSEK 2.21BSEK 1.76B
Capital expenditureSEK 1.00BSEK 1.07BSEK 1.57BSEK 1.64BSEK 1.56B
Total debtSEK 6.83BSEK 7.33BSEK 7.57BSEK 7.25BSEK 6.67B

Quarterly statements and history in the cockpit →

Elekta competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-25%0%+25%300529688029NEOG0029012276MOVEEBOMETNDRW86951ESTAOBCKVCYTBONEXCELCATRCMEDSKANEKTA-B.ST6-month return →1-month return →
Up and to the right = strong over both horizons. Elekta is the large dot.

Fundamentals: revenue growth against valuation

0%+20%0×100×200×300529688029NEOG0029012276EBOMETNDRW86951VCYTBONEXCOTNATRCMEDSKANEKTA-B.STRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Elekta is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%3005296880290029012276EBODRW86951OBCKVCYTBONEXATRCSKANEKTA-B.STGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Elekta is the large dot.

Elekta competitors and peer comparison

Head to head with its named competitors (EKTA-B.ST vs SHL.DE vs ARAY vs 688271.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Elekta EKTA-B.ST$2.35B0%-7%6%15.3×10.7%
Siemens Healthineers SHL.DE$53.7B+27%+1%14%18.9×9.6%
Accuray ARAYn/a-81%n/an/an/an/a
Shanghai United Imaging Healthcare 688271.SS$14.4B+4%+27%9%45.7×n/a

How Elekta compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Elekta against its 20 peers (data as of 18 Nov 2026)
MeasureEKTA-B.STPeer medianRank in peer set
1-month return+12.0%-1.6%6th highest of 21
6-month return-0.1%+1.1%10th lowest of 20
Distance from 52-week high-6.3%-24.0%3rd highest of 21
Revenue growth (TTM)-6.9%+7.5%2nd lowest of 20
Operating margin6.3%11.8%7th lowest of 20
Forward P/E15.3×24.3×3rd cheapest of 18
Growth the price implies (Req g, 7 yrs)10.7%9.7%7th least demanding of 13
Growth delivered (Del g)+4.0%+11.1%3rd lowest of 13
Hurdle (Req g minus delivered)+6.8 pp-5.1 pp3rd most demanding of 13
ROIC minus cost of capital-0.6 pp+1.8 pp10th lowest of 20
EV / EBITDA16.1×25.7×6th cheapest of 14
Net debt / EBITDA2.6×0.1×4th most indebted of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Elekta EKTA-B.STSweden$2.35B0%-7%6%15.3×10.7%+4.0%
Jafron Biomedical 300529.SZChina$2.35B+3%+1%37%24.3×6.1%+0.6%
Micro-Tech (Nanjing) 688029.SSChina$2.33B0%+6%18%28.1×11.9%+19.2%
Neogen NEOGUnited States$2.42B+25%0%0%32.6×n/an/a
Double Medical Technology 002901.SZChina$2.43B-2%+13%26%24.2×7.6%+10.4%
Shanghai Conant Optical 2276.HKHong Kong$2.25B-17%+8%29%22.1×-1.1%+14.1%
Medacta MOVE.SWSwitzerland$2.48B-28%+8%15%24.0×n/an/a
EBOS EBO.AXAustralia$2.50B+7%+3%3%15.7×4.7%+6.8%
Metall Zug METN.SWSwitzerland$2.19B+20%0%-10%139.8×n/an/a
Draegerwerk AG & Co. KGaA DRW8.DEGermany$2.13B+25%+5%7%10.2×-10.2%+0.4%
JEOL 6951.TJapan$2.12B-2%-15%12%15.5×22.2%+10.2%
Establishment Labs ESTAUnited States$2.11B+1%+38%-7%n/an/an/a
Ottobock SE & Co. KGaA OBCK.DEGermany$2.65B-30%+5%17%12.3×-1.2%+8.0%
Veracyte VCYTUnited States$2.06B-43%+18%16%17.1×18.0%+34.5%
Bonesupport BONEX.STSweden$2.06B+21%+25%25%61.5×12.6%+45.4%
Celcuity CELCUnited States$2.73B-60%n/an/an/an/an/a
COMET COTN.SWSwitzerland$2.78B-15%-3%6%32.8×n/an/a
AtriCure ATRCUnited States$2.82B+91%+14%3%212.4×54.2%+20.9%
Medartis MED.SWSwitzerland$1.86B+47%+30%2%72.8×n/an/a
SKAN SKAN.SWSwitzerland$1.85B+40%+9%11%49.5×13.8%+11.7%
Molbio Diagnostics MOLBIO.NSIndia$1.85Bn/a+35%17%n/an/an/a

Questions

Who are Elekta's main competitors?
Named competitors: Varian Medical Systems (Siemens Healthineers) (SHL.DE), Accuray (ARAY), Siemens Healthineers (SHL.DE), United Imaging Healthcare (688271.SS). The cockpit's measured peer set (industry) also includes Jafron Biomedical (300529.SZ), Micro-Tech (Nanjing) (688029.SS), Neogen (NEOG), Double Medical Technology (002901.SZ), Shanghai Conant Optical (2276.HK), Medacta (MOVE.SW).
Is Elekta expensive compared with its peers?
On forward p/e it trades at 15.3× against a peer median of 24.3×, 3rd cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +7 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Elekta stock performed?
Over six months to 18 Nov 2026 the shares returned -0.1% against +1.1% for the median peer; over one year +38.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.